Lilly’s LY-CoV555 Shows Promise Targeting COVID-19 With Phase 2 Interim Analysis

Eli Lilly and Company (NYSE: LLY) announced that proof of concept data from an interim analysis of the BLAZE-1 clinical trial reveals a reduced rate of hospitalization for patients treated with LY-CoV555. An ongoing randomized, double-blind, placebo-controlled Phase 2 study reveals centers on the investigational product known as LY-CoV555. Developed thanks to a partnership affording access to powerful drug discovery technology from AbCellera, in combination with dedicated Lilly scientists working day and night starting back in the early Spring, this potent monoclonal antibody demonstrates real promise as a regimen targeting both COVID-19 prevention and treatment.


